General Injectables and Vaccines (GIV) to market EZ Detect in US:
This article was originally published in Clinica
General Injectables & Vaccines will market Biomerica's EZ Detect stool blood test to US physician hospitals, HMOs and nursing homes. The exclusive US marketing agreement is expected to generate sales of at least $4 million for Biomerica in the first three years. The two-minute home test is used to detect occult blood in the stool.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.